Vir Biotechnology, Inc. (VIR), a clinical-stage biopharmaceutical company, on Wednesday announced encouraging early data from its ongoing Phase 1 trials of dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting solid tumors and metastatic castration-resistant prostate cancer, respectively.
VIR-5818 is a T-cell engager targeting HER2-expressing cancers, and VIR-5500 targets PSMA in mCRPC. The trials are evaluating the safety, pharmacokinetics, and efficacy of these candidates in heavily pretreated patients.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.